The role of the antidiabetic drug metformin in the treatment of endocrine tumors.

Brianna Daley,J. Klubo-Gwiezdzinska,Shilpa Thakur

DOI: https://doi.org/10.1530/JME-19-0083

2019-08-01

Journal of Molecular Endocrinology

Abstract:Incidence of endocrine cancers is rising every year. Over the last decade, evidence has accumulated that demonstrates the anti-cancer effects of an anti-diabetic drug - metformin - in endocrine malignancies. We performed a literature review utilizing the Pubmed, Medline and clinicaltrials.gov databases using the keyword "metformin" plus the following terms: "thyroid cancer," "thyroid nodules," "parathyroid," "hyperparathyroidism," "adrenal adenoma," "Cushing syndrome," "hyperaldosteronism," "adrenocortical cancer," "neuroendocrine tumor (NET)," "pancreatic NET (pNET)," "carcinoid," "pituitary adenoma," "pituitary neuroendocrine tumor (PitNET)", "prolactinoma," "pheochromocytoma/paraganglioma." We found 37 studies describing the preclinical and clinical role of metformin in endocrine tumors. The available epidemiological data shows an association between exposure of metformin and lower incidence of thyroid cancer and pNETs in diabetic patients. Metformin treatment has been associated with better response to cancer therapy in thyroid cancer and pNETs. Preclinical evidence suggests that the primary direct mechanisms of metformin action include inhibition of mitochondrial oxidative phosphorylation via inhibition of both mitochondrial complex I and mitochondrial glycerophosphate dehydrogenase, leading to metabolic stress. Decreased ATP production leads to an activation of a cellular energy sensor, AMPK, and subsequent downregulation of mTOR signaling pathway, which is associated with decreased cellular proliferation. We also describe several AMPK-independent mechanisms of metformin action, as well as the indirect mechanisms targeting insulin resistance. Overall, repositioning of metformin has emerged as a promising strategy for adjuvant therapy of endocrine tumors. The mechanisms of synergy between metformin and other anti-cancer agents need to be elucidated further to guide well-designed prospective trials on combination therapies in endocrine malignancies.

Medicine

What problem does this paper attempt to address?

The paper primarily explores the potential role and mechanisms of metformin in the treatment of endocrine tumors. It points out that metformin was initially widely used as an anti-diabetic drug, but recent studies have found that it has anti-cancer effects. Specifically, the study summarizes the application of metformin in endocrine tumors such as thyroid cancer and pancreatic neuroendocrine tumors (pNETs), and analyzes its possible mechanisms of action.

1. **Thyroid Cancer**: Research shows that in vitro experiments, metformin can inhibit the growth of thyroid cancer cell lines, which is related to AMPK activation and inhibition of the mTOR signaling pathway. Additionally, clinical data indicate that the incidence of thyroid cancer is lower in diabetic patients who have been taking metformin for a long time.

2. **Pancreatic Neuroendocrine Tumors (pNETs)**: Metformin also shows inhibitory effects on pNETs by reducing cell proliferation through the inhibition of mitochondrial oxidative phosphorylation and the mTOR signaling pathway.

3. **Other Endocrine Tumors**: The study also explores the role of metformin in other types of endocrine tumors, such as medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC), although data in these areas are relatively scarce.

In summary, this paper aims to reveal the potential of metformin in the treatment of endocrine tumors and to explore its possible molecular mechanisms, providing a theoretical basis for further clinical trials.